[Neoadjuvant systemic chemotherapy with VMC (vinblastine, methotrexate and cisplatin) in locally advanced carcinoma of the bladder].
A total of 25 patients with locally advanced bladder cancer, staged T3 and T4, have received neo-adjuvant VMC chemotherapy with Vinblastine, Methotrexate and Cisplatinum. The evaluable patients were 21 and after cystectomy demonstrated the following responses: pCR in one case (4%), pRP in ten cases (48%), pNC in 10 patients (48%). Toxicity was mainly represented by leukopenia in 18 patients (82%), one of them died from neutropenic sepsis. After a median follow-up time of 12 months (range 6-39) 5 patients already experienced relapse of the disease.
Maffezzini
M
M
Istituto Scientifico San Raffaele, Divisione di Urologia.
Rigatti
P
P
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009367:Neoplasm Staging; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D002945:Cisplatin; D008727:Methotrexate
Chemioterapia sistemica neoadiuvante con VMC (vinblastina, metothrexate e cisplatino) nei carcinomi della vescica localmente avanzati.